{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Bajda S"],"funding":["Bundesministerium für Bildung und Forschung","Projekt DEAL"],"pagination":["19594"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7658229"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["10(1)"],"pubmed_abstract":["Epstein-Barr virus (EBV) reactivation can lead to serious complications in kidney transplant patients, including post-transplant lymphoproliferative disorder (PTLD). Here, we have assessed the impact of EBV on B cell homeostasis at cellular and humoral level. In a multicenter study monitoring 540 kidney transplant patients during the first post-transplant year, EBV reactivation was detected in 109 patients. Thirteen soluble factors and B cell counts were analyzed in an EBV<sup>+</sup> sub-cohort (N = 54) before, at peak and after EBV clearance and compared to a control group (N = 50). The B cell activating factor (BAFF) was significantly elevated among EBV<sup>+</sup> patients. No additional soluble factors were associated with EBV. Importantly, in vitro experiments confirmed the proliferative effect of BAFF on EBV-infected B cells, simultaneously promoting EBV production. In contrast, elevated levels of BAFF in EBV<sup>+</sup> patients did not lead to B cell expansion in vivo. Moreover, diminished positive inter-correlations of soluble factors and alterations of the bi-directional interplay between B cell and soluble factors were observed in EBV<sup>+</sup> patients at peak and after clearance. Our data suggest that such alterations may counteract the proliferative effect of BAFF, preventing B cell expansion. The role of these alterations in lymphoma development should be analyzed in future studies."],"journal":["Scientific reports"],"pubmed_title":["The role of soluble mediators in the clinical course of EBV infection and B cell homeostasis after kidney transplantation."],"pmcid":["PMC7658229"],"funding_grant_id":["eKID"],"pubmed_authors":["Reinke P","Samans B","Hugo C","Olek S","Westhoff TH","Kaliszczyk S","Blazquez-Navarro A","Babel N","Roch T","Witzke O","Amini L","Dittmer U","Schmueck-Henneresse M","Viebahn R","Wehler P","Bajda S","Thomusch O"],"additional_accession":[]},"is_claimable":false,"name":"The role of soluble mediators in the clinical course of EBV infection and B cell homeostasis after kidney transplantation.","description":"Epstein-Barr virus (EBV) reactivation can lead to serious complications in kidney transplant patients, including post-transplant lymphoproliferative disorder (PTLD). Here, we have assessed the impact of EBV on B cell homeostasis at cellular and humoral level. In a multicenter study monitoring 540 kidney transplant patients during the first post-transplant year, EBV reactivation was detected in 109 patients. Thirteen soluble factors and B cell counts were analyzed in an EBV<sup>+</sup> sub-cohort (N = 54) before, at peak and after EBV clearance and compared to a control group (N = 50). The B cell activating factor (BAFF) was significantly elevated among EBV<sup>+</sup> patients. No additional soluble factors were associated with EBV. Importantly, in vitro experiments confirmed the proliferative effect of BAFF on EBV-infected B cells, simultaneously promoting EBV production. In contrast, elevated levels of BAFF in EBV<sup>+</sup> patients did not lead to B cell expansion in vivo. Moreover, diminished positive inter-correlations of soluble factors and alterations of the bi-directional interplay between B cell and soluble factors were observed in EBV<sup>+</sup> patients at peak and after clearance. Our data suggest that such alterations may counteract the proliferative effect of BAFF, preventing B cell expansion. The role of these alterations in lymphoma development should be analyzed in future studies.","dates":{"release":"2020-01-01T00:00:00Z","publication":"2020 Nov","modification":"2025-04-26T16:49:14.078Z","creation":"2020-11-19T15:24:19Z"},"accession":"S-EPMC7658229","cross_references":{"pubmed":["33177622"],"doi":["10.1038/s41598-020-76607-z"]}}